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Abstract
Background: The initial use of BRAF targeted therapeutics in clinical trials has demonstrated encouraging
responses in melanoma patients, although a rise in drug-resistant cells capable of advancing malignant disease has
been described. The current study uses BRAF
V600E expressing WM793 melanoma cells to derive data aimed at
investigating the molecular determinant of cell invasion following treatment with clinical BRAF inhibitors.
Findings: Small-molecule inhibitors targeting BRAF reduced MEK1/2-ERK1/2 pathway activation and cell survival;
yet, viable cell subpopulations persisted. The residual cells exhibited an elongated cell shape, prominent actin stress
fibers and retained the ability to invade 3-D dermal-like microenvironments. BRAF inhibitor treatments were
associated with reduced expression of RND3, an antagonist of RHOA activation, and elevated RHOA-dependent
signaling. Restoration of RND3 expression or RHOA knockdown attenuated the migratory ability of residual cells
without affecting overall cell survival. The invasive ability of BRAF inhibitor treated cells embedded in collagen gels
was diminished following RND3 re-expression or RHOA depletion. Conversely, melanoma cell movement in the
absence of BRAF inhibition was unaffected by RND3 expression or RHOA depletion.
Conclusion: These data reveal a novel switch in the requirement for RND3 and RHOA in coordinating the
movement of residual WM793 cells that are initially refractive to BRAF inhibitor therapy. These results have
important clinical implications because they suggest that combining BRAF inhibitors with therapies that target the
invasion of drug-resistant cells could aid in controlling disease relapse.
Findings
Cutaneous melanoma is the most lethal skin cancer and
its incidence rates continues to rise [1]. Clinical grade
small molecule inhibitors targeting BRAF have recently
emerged due to its frequent mutational status [2] and
vital role in malignancy [3,4]. In particular, a structure-
based approach led to the development of PLX-4720, a
potent inhibitor of BRAF kinase activity with a V600E
mutation [5]. PLX-4720 selectively inhibits MEK1/2-
ERK1/2 activation, cell proliferation and xenograph
tumor growth using mutant BRAF expressing cell lines
[5,6]. PLX-4720 is an analog of the clinically tested
PLX-4032 (aka RG7204/Vermurafenib) compound
which has demonstrated favorable therapeutic responses
[7-9]. Although the durability of PLX-4032 is still under
investigation, tumor relapse has been reported [7,8].
A combination of strategies has been suggested to be
required for successful therapeutic outcomes in mela-
noma [10,11]. The addition of an anti-invasive agent to
complement targeted BRAF inhibition constitutes an
additional therapy that may improve patient outcomes
by preventing or delaying the dissemination of drug-
resistant clones; however, little is known regarding mela-
noma invasive strategies following BRAF inhibition.
RND3-RHOA cell signaling was identified as a mutant-
BRAF regulated pathway [12] that coordinates cell
movement [13]. RND3 is an atypical RHO-GTPase [14]
that antagonizes RHO-ROCKI signaling [15,16].
Whether this pathway participates in melanoma invasion
following BRAF inhibition is unknown.
Human WM793 melanoma cells express BRAF
V600E
[17] and are hemizygously deleted for PTEN with a
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knockdown of BRAF rather than ARAF or CRAF
reduces MEK1/2-ERK1/2 phosphorylation (Additional
file 1, Figure S1). Likewise, pharmaceutical inhibition of
BRAF elicited dose-dependent reductions in MEK1/2
phosphorylation (Figure 1A). ERK1/2 phosphorylation
decreased ~92% in cells treated with either 0.5 μMS B -
590885, a potent inhibitor of total BRAF [19] or 0.5 μM
PLX-4720, the BRAF
V600E selective inhibitor (Figure 1B).
Interestingly, numerous cells remained attached and
well spread following inhibitor treatments (Figure 1C),
suggesting survival may not have been negatively
impacted. Viable cells were identified following 96 h
incubations with either SB-590885 or PLX-4720 (Figure
1D). Cell viability was further evaluated after re-plating
onto non-fibrillar collagen gels, in the continued pre-
sence of the drugs. BRAF inhibition led to dramatic
morphological changes; cells appeared elongated and
less refractive compared to control cells (Figure 2A).
Viable cells were identified in ~59% of SB-590885 and
~63% of PLX-4720 treated cultures (Additional file 2,
Figure S2). These data indicate that melanoma cells har-
boring a BRAF
V600E mutation can survive despite reduc-
tions in BRAF activation of the MEK-ERK signaling
cascade.
BRAF knockdown alters cytoskeletal architecture and
cell shape [12]; therefore, it was important to assess
whether alterations in F-actin also accompanied phar-
maceutical BRAF inhibition. Control cells plated on col-
lagen gels exhibited diffuse microfilament staining
patterns with thin cortical fibers (Figure 2B). In contrast,
prominent F-actin stress fibers typified BRAF inhibitor
treated cells (Figure 2B); these stress fiber traversed the
cell body often terminating in large bundles at the cell
membrane. Cell elongation and prominent actin stress
fibers, therefore, correlate with viable melanoma cells in
the presence of BRAF inhibitors.
To determine if drug insensitivity occurred in a more
physiological setting melanoma spheroids embedded
into a 3-D collagen gel, to recapitulate a stromal-like
environment [10], were treated with inhibitors in com-
plete medium. Controls cultures invaded the surround-
ing extracellular matrix (Figure 2C). SB-590885 and
PLX-4720 treatment attenuated invasive outgrowth (Fig-
ure 2C), although some spheroids were surrounded with
elongated cells that invaded the surrounding microenvir-
onment (Figure 2C). Invasive cells were evident in 33%
and 36% of spheroid structures treated with SB-590885
and PLX-4720, respectively, (Figure 2D) clearly signify-
ing that some cells can invade a 3-D microenvironment
following pharmaceutical BRAF inhibition.
Alterations in BRAF regulated signaling pathways that
could affect actin organization and melanoma invasion
were then evaluated. RND3 expression is increased in
invasive melanoma cells expressing BRAF
V600E [13] and
is a known regulator of actin organization [14]. There-
fore, we assessed whether BRAF inhibitors had an effect
on RND3. Western blot analysis indicated that reduced
RND3 expression accompanied pharmaceutical inhibi-
tion of BRAF (Figure 3A). We then constructed a doxy-
cycline-inducible myc-tagged RND3 expression system
to determine if reduced RND3 expression was required
for melanoma invasion in the presence of BRAF inhibi-
tors. This system allowed for sustained RND3 expres-
sion despite reduced BRAF signaling to ERK1/2 (Figure
3B). Inducible expression of RND3 did not affect ERK1/
2 activation or inhibition (Figure 3B). The functionality
of ectopic RND3 expression was confirmed by micro-
scopic evaluation of F-actin staining. RND3 over-expres-
sion attenuated the formation of actin stress fibers in
response to BRAF inhibition (Additional file 3, Figure
S3A), although, sustained RND3 expression did not pre-
vent increases in cofilin phosphorylation which accom-
panied BRAF inhibition (Additional file 3, Figure S3B).
The effect increased RND3 expression had on cell
growth was then assessed. Induced RND3 expression
did not affect basal growth nor did it alter reductions in
cell growth associated with BRAF inhibition (Figure 3C).
It was important, therefore, to evaluate the effect restor-
ing RND3 expression had on the migration of BRAF
inhibitor treated cells. BRAF inhibition reduced cell
migration by approximately 85% (Figure 3D). Ectopic
RND3 did not affect basal cell migration, although, its
sustained expression significantly diminished the migra-
tion of PLX-4720 treated cells (Figure 3D). To deter-
mine if reduced RND3 expression was required for the
invasion of BRAF inhibitor treated cells, we monitored
the invasive outgrowth of PLX-4720 treated spheroids
embedded into collagen gels in the presence or absence
of RND3. Sustained RND3 expression significantly
reduced (~24%) the frequency of invasive cells evident
in PLX-4720 treated cultures (Figure 3C and 3D),
whereas, it did not affect non-treated spheroids (Figure
3C and 3D). Thus, reduced RND3 expression supports
melanoma invasion following BRAF inhibition.
In invasive melanoma, RND3 expression regulates
actin organization through RHOA [12]. To investigate
whether BRAF inhibitors enhanced RHOA-dependent
signaling, we monitored the activation of the down-
stream RHOA-ROCK1/2 effector, myosin regulatory
light chain. Treatment of cells with PLX-4720 or SB-
590885 resulted in increased phosphorylation of myosin
light chain 2 (Figure 4A), suggestive of enhanced RHOA
signaling. To establish whether RHOA was required for
melanoma invasion despite BRAF inhibition, RHOA
knockdown cells were generated. Inducible depletion of
RHOA by shRNA in the absence or presence of PLX-
4720 was confirmed by Western blot (Figure 4B).
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Figure 1 A sub-population of viable melanoma cells persist following BRAF inhibition. Invasive WM793 human melanoma cell layers
treated 48 h with DMSO or pharmacological inhibitors targeting total BRAF (SB-590885) or mutant BRAF (PLX-4720) from B-Bridge Int.
(Cupertino, CA). A) Cell layers were treated with increasing concentration (0.01, 0.05, 0.1, 0.5, 1.0 μM) of inhibitors, cell lysates were generated
and analyzed by Western blot using antibodies from Cell Signaling Technology (Danvers, MA); phos-MEK1/2 (9121) and total MEK1 (9124). B)
Western blot analysis of lysates from cells treated with 0.5 μM SB-590885, 0.5 μM PLX-4720 or DMSO, phos-ERK1/2 (sc7383) and total ERK2
(sc154) antibodies from Santa Cruz Biotech (Santa Cruz, CA). Graphed is the mean ± SD of phos-ERK1/2:ERK2 ratio from 3 experiments with the
DMSO condition set to one. C) Micrographs depicting cell layers treated with inhibitors, as described above. D) Time-course indicating viable
melanoma cells following BRAF inhibitor treatments, as determined by toludine blue staining; Graph shows average ± SD).
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Page 3 of 8RHOA knockdown did not affect drug inhibition of ERK
phosphorylation, although, depletion of RHOA was
functional as observed by the prevention of increased
myosin light chain 2 phosphorylation (Figure 4B) and
actin stress fiber formation following BRAF inhibition
(Additional file 4, Figure S4A). Knockdown of RHOA
did not impact the increase in cofilin phosphorylation
(Additional file 4, Figure S4B) or reduction in cell
growth that accompanied BRAF inhibition (Figure 4C).
RHOA depletion (Figure 4D), and ROCKI/II inhibition
(Additional file 5, Figure S5), attenuated cell migration
in PLX-4720 treated cultures. The requirement for
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Figure 2 Phenotypic characterization of cells treated with pharmaceutical BRAF inhibitors. A, B) Melanoma cells treated ± inhibitors 48 h
with 0.5 μM SB-590885, 0.5 μM PLX-4720 or DMSO. Adherent cells were trypsinized and plated on top a collagen gel [13] for an additional 24 h
in the continued presence of inhibitors. A) Cell morphology of control (DMSO) or BRAF inhibitor treated cultures, visualized using phase-contrast
microscopy. B) Fluorescent visualization of F-actin organization, TRITC-conjugated phalloidin (P1951) was from Sigma-Aldrich (St. Louis, MO). C)
Phase contrast images of melanoma spheroids that were embedded in a collagen gel for three days ± inhibitors [10]. D) Quantitation of
spheroids, shown in (C), that contains cells insensitive to BRAF inhibitors. (Graph shows average ± SD; *P < 0.05).
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Figure 3 RND3 downregulation participates in the invasion of melanoma cells insensitive to BRAF inhibition. A) Immunoblot of lysates
from cells treated 48 h with 0.5 μM SB-590885, 0.5 μM PLX-4720 or DMSO using antibodies directed toward RND3 (05-723 from Upstate Biotech
Inc.) and total ERK2. B-F) Inducible expression of myc-tagged wild-type RND3 in WM793 melanoma cells cultured in complete medium ±
doxycycline (Dox) in the absence or presence of PLX-4720. B) Western blot of cell lysates using antibodies specific for myc-tag, RND3, phos-
ERK1/2 and ERK2. C) The viability of cells, treated as in (A), cultured four days was monitored by Toludine blue staining, graphed are the results
from one experiment performed in triplicate. D) Cells, treated as in (A), plated in serum-free medium into the upper well of a Boyden migration
chamber pre-coated with fibronectin + collagen mixture (10 μg/ml). The lower well contained complete medium, to stimulate cell migration.
Sixteen hours later, cells that migrated to the insert bottom were labeled with Hoescht Dye and counted by fluorescent microscopy. E)
Micrographs depicting invasive outgrowth of spheroids, treated as indicated, embedded inside a 3-D collagen gel. F) Quantitation of the
number of spheroids that contained invasive cells, as depicted in (E). All experiments were performed in triplicate. The graphs presented
represent mean ± SD, statistical significance determined using Student’s t-test and P-values < 0.05 considered significant (*).
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Figure 4 Endogenous RHOA depletion antagonizes the invasion of melanoma cells that are insensitive to BRAF inhibition. A) Lysates
generated from cells treated 48 h with 0.5 μM SB-590885, 0.5 μM PLX-4720 or DMSO, subjected to Western blot analysis using antibodies
specific for phosphorylated (Thr18/Ser19) myosin light chain 2 (Cell Signaling #3674) and actin. B) Dox-inducible RHOA shRNA (target sequence:
ATGGAAAGCAGGTAGAGTT) melanoma cells were treated ± 0.5 μM PLX-4720 for 48 h. Cell lysate analyzed by Western blot for RHOA (sc418),
phos-MLC2, phos-ERK1/2 and ERK2. C) The viability of cells, treated as in (B), monitored by toludine blue staining, representative graph of the
results from one experiment performed in triplicate. D) Boyden chamber analysis of cell migration (as described in Figure 3D) following
treatments shown in (B). Graph indicates average number of migrated cells ± SD. E) Micrographs of invasive outgrowth associated with
inducible RHOA shRNA spheroids in the presence or absence of mutant BRAF inhibition. F) Quantitation (average ± SD) of the number of
spheroids, as depicted in (E), that harbor drug refractive cells. All experiments were performed in triplicate. Statistical significance determined
using Student’s t-test and P-values < 0.05 were considered significant and represented by *.
Klein and Higgins Molecular Cancer 2011, 10:114
http://www.molecular-cancer.com/content/10/1/114
Page 6 of 8RHOA in the 3-D invasive outgrowth of melanoma
spheroids in the presence of PLX-4720 was then evalu-
ated. Depletion of RHOA alone did not affect invasive
outgrowth (Figure 4E and 4F). However, the combina-
tion of PLX-4720 treatment and RHOA knockdown
further reduced the number of spheroids that contained
invasive cells by ~26% (Figure 4E and 4F). These results
demonstrate that RHOA participates in residual mela-
noma cell invasion following pharmaceutical BRAF
inhibition.
Cancer cell resistance to cytotoxic agents is a com-
mon and severe therapeutic impediment that can lead
to the reemergence of malignant tumors. This study
demonstrates that a subpopulation of melanoma cells
can survive and invade a dermal-like extracellular
matrix, despite BRAF inhibitor treatments. These find-
ings agree with others who have shown that melanoma
cell lines expressing a BRAF
V600E mutation can estab-
lished resistance to BRAF inhibitors in culture [20,21]
as well as a xenograph mouse model [22]. Moreover,
despite encouraging clinical trial outcomes using PLX-
4032 [7,8], the development of BRAF inhibitor resis-
tant cells has been reported [23-25]. Collectively these
studies advocate for the preparation of therapies that
prevent the development of drug-insensitive clones or
block the ability of these cells to spread and
metastasize.
The present work identifies factors that facilitate the
residual invasion of BRAF
V600E expressing melanoma
cells after pharmaceutical BRAF inhibition by employ-
ing 2-D and more physiological 3-D preclinical models.
Initially, an elongated cell shape with prominent actin
stress fibers were identified as phenotypic markers of
viable cells following BRAF inhibition. Importantly, the
correlation between cytoskeletal remodeling and drug
insensitivity does not implicate prominent actin stress
fibers as a predictive factor or “biomarker” for mela-
noma resistance to BRAF inhibition. The development
of actin stress fibers more closely reflects enhanced
RHOA pathway signaling. The current study identifies
novel roles for RND3 and RHOA in the movement but
not growth or survival of melanoma cells treated with
BRAF inhibitors. These findings suggest that BRAF
inhibition invokes a switch in the utilization of the
RND3-RHOA signaling pathway. Accordingly, RND3
expression and suppressed RHOA signaling appear to
be important for normal melanoma cell movement,
whereas RND3 downregulation and enhanced RHOA
signaling are critical in BRAF-inhibitor treated cells.
Collectively, these data demonstrate that interfering
with signaling pathways which facilitate the invasion of
drug-resistant tumor cells may represents a cytostatic
therapy that could complement BRAF inhibitor
therapeutics.
Additional material
Additional file 1: BRAF supports elevated ERK1/2 phosphorylation
in WM793 melanoma cells. WM793 melanoma cells treated 72 h with
siRNA from Dharmacon targeting ARAF (L-003563-00), BRAF (L-003460-
00), CRAF (L-006301-00) or non-targeting control (D-001210-01) using
oligofectamine. Cell lysates were generated and immunoblotted using
antibodies from Santa Cruz Biotech (Santa Cruz, CA): ARAF (sc407), BRAF
(sc5284), CRAF (sc133), phos-ERK1/2 (sc7383) and total ERK2 (sc154).
Additional file 2: Viable melanoma cells persist following BRAF
inhibition. Invasive WM793 human melanoma cells treated with
pharmacological inhibitors targeting total BRAF (0.5 μM SB-590885),
mutant BRAF (0.5 μM PLX-4720) or equal volume DMSO. Cell layers
incubated ± inhibitors 48 h then seeded on top a collagen gel an
additional 24 h in the continued presence of inhibitors. A) Representative
images from dual-fluorescent cell viability assay; Calcein-AM - live cells,
EthD-1 - dead cells (Invitrogen). B) Quantitation of live/dead cells
counted on collagen gels, as shown in (A). Graph shows mean ± SD %
of live cells counted from three independent experiments (n = 300).
Additional file 3: RND3 restoration disrupts PLX-4720 induced actin
stress fiber formation. A) Micrographs depicting F-actin organization in
Dox-inducible RND3 expressing WM793 melanoma cells treated with 0.5
μM PLX-4720 or equal volume DMSO. Cells incubated ± inhibitors 48 h
were then seeded on top a collagen gel an additional 24 h in the
continued presence of inhibitors. Cell layers were then were fixed and
processed to visualize F-actin organization. B) Cell lysates generated and
immunoblotted using antibodies from Cell Signaling Tech. (Danvers, MA):
phospho-Cofilin (3311) and Santa Cruz Biotech (Santa Cruz, CA): total
ERK2 (sc154).
Additional file 4: RHOA is required for PLX-4720 induced actin
stress fiber formation. A) Micrographs depicting F-actin organization in
Dox-inducible RHOA shRNA expressing WM793 melanoma cells treated
with 0.5 μM PLX-4720 or equal volume DMSO. Cells incubated ±
inhibitors 48 h were then seeded on top a collagen gel an additional 24
h in the continued presence of inhibitors. Cell layers were then were
fixed and processed to visualize F-actin organization. B) Cell lysates
generated and immunoblotted using antibodies from Cell Signaling
Tech. (Danvers, MA): phospho-Cofilin (3311) and Santa Cruz Biotech
(Santa Cruz, CA): total ERK2 (sc154).
Additional file 5: ROCKI/II are utilized for residual cell migration
following PLX-4720 treatment. Cells treated 48 hours ± 0.5 μM PLX-
4720 were plated into the upper well of a Boyden migration chamber
pre-coated with a fibronectin + collagen mixture (10 μg/ml) in the
absence or presence of 5 μM Y27632, a ROCKI/II inhibitor. The lower well
contained complete medium in the absence or presence of inhibitors, as
indicated, to stimulate cell migration. Sixteen hours later, cells that
migrated to the insert bottom were labeled with Hoescht Dye and
counted by fluorescent microscopy. A) Micrographs depicting migrated
cells. B) Graph indicates average number of migrated cells ± SD.
Statistical significance (*) determined by Student’s t-test (P-value = .048).
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